HIMS Hers Stock: What You Need to Know

Hims & Hers Health is the oddest fit in the Motley Fool’s “King Kong for Weight Loss” basket, and that is precisely what makes it worth understanding. It is not a drug developer like the other picks. It is a telehealth company that sells a branded, consumer-facing product, and its weight-loss business is built on a legal shortcut that carries a specific, well-known regulatory risk. Here is what Hims & Hers actually does and where that risk sits.

What Hims & Hers Is

Hims & Hers Health (HIMS) is a direct-to-consumer telehealth platform. It started selling treatments for things like hair loss, skin care, and sexual health, and it has since expanded aggressively into the weight-loss market through compounded semaglutide. Compounded drugs are not the branded originals. They are made by specialized pharmacies, and they are only allowed under a specific legal carve-out: when the branded drug is in shortage, compounding pharmacies can produce versions of it.

That shortage window is the entire foundation of Hims & Hers’ GLP-1 business. When semaglutide is officially listed as being in short supply, compounded copies are legal. When the shortage ends, that legal basis is supposed to wind down. This is not a secret, and it is the single most important thing to understand about the company as a weight-loss investment.

The logic for including Hims & Hers is straightforward. Weight-loss drugs are expensive and often not covered by insurance, so there is a large population of patients who want the medicine but cannot easily get the branded version. Compounded semaglutide is dramatically cheaper, and Hims & Hers has built a slick, convenient funnel to sell it directly to consumers. That is a real business, and it grew fast.

But there is a reason the branded makers and regulators watch this space closely. Compounded GLP-1s sit in a gray zone that exists only because of the shortage. The FDA has already signaled that as the shortage resolves, compounded supply is expected to wind down. That is not a theoretical risk; it is the stated regulatory trajectory.

The Growth and the Overhang

Hims & Hers has real revenue and a fast-growing subscriber base, which separates it from the pre-revenue biotechs in the basket like Viking Therapeutics and Veru. The stock trades in the high $20s, and the company has shown it can acquire customers at scale. That is the bull case, and it is not trivial.

The bear case is the overhang. If the semaglutide shortage resolves, Hims & Hers loses the legal basis for its core weight-loss product, and it has to pivot its customer base toward branded products or other treatments. The promo’s “playing field is about to be redrawn” framing is optimistic here, because the redrawing cuts against the compounded model, not for it. The company is also not developing its own drug, so it has no pipeline to fall back on the way Ascendis Pharma or Eli Lilly do.

How It Compares to the Rest of the Basket

Among the six picks, Hims & Hers is the only pure consumer-platform play. Eli Lilly is a trillion-dollar pharma giant with the marquee drug. Ascendis Pharma is a revenue-growing biotech with a once-monthly semaglutide. Viking Therapeutics and Veru are pre-revenue clinical bets. Scholar Rock is not even a weight-loss company, its lead asset treats spinal muscular atrophy. Hims & Hers is different from all of them: it is a distribution play on the compounded-drug window, not a bet on a molecule.

That distinction matters for sizing. A telehealth distribution business and a clinical-stage drug developer have entirely different risk profiles, even if the promo wraps them under one “weight loss” label. Our King Kong weight loss teardown breaks down how different those six profiles really are.

The Bottom Line

Hims & Hers has built a fast-growing, consumer-friendly telehealth business, and the compounded-GLP-1 market is a real source of revenue today. But the entire weight-loss segment rests on a shortage-based legal carve-out that regulators intend to close. Investors weighing this name should price in that regulatory transition rather than extrapolating the current growth rate indefinitely. For the broader healthcare-stocks context, see our AI healthcare stocks piece.

The Pivot Question

The central question for Hims & Hers is what happens when the shortage ends and compounded semaglutide loses its legal footing. The company has options: it can market branded drugs through its telehealth funnel, it can lean on the rest of its portfolio, which spans far more than weight loss, and it can build out new treatment categories the way it built the GLP-1 line. The bull case is that the customer base and the brand survive the transition even if the specific product does not. The bear case is that the weight-loss segment was the growth engine, and the rest of the business does not fill the gap at the same margin. Either way, the answer depends on execution over the next couple of years, which is a different kind of risk than a clinical readout, but a real one all the same.

Ready to see the research? Click here to access The Motley Fool’s report.